Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group

Item
http://www.wikidata.org/entity/Q34915389
Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessA Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudySystematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Novel microtubule-targeting agents - the epothilones.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentOutcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move ForwardIdentification of Synergistic, Clinically Achievable, Combination Therapies for OsteosarcomaInitial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial EfficiencyAdvances in therapy for pediatric sarcomas.Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group.Voices of children and adolescents on phase 1 or phase 2 cancer trials: A new trial endpoint?Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.
P2860

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group

Item
http://www.wikidata.org/entity/Q34915389
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II trial of ixabepilone ...... the children's oncology group
@ast
Phase II trial of ixabepilone ...... the children's oncology group
@en
Phase II trial of ixabepilone ...... the children's oncology group
@nl
type
label
Phase II trial of ixabepilone ...... the children's oncology group
@ast
Phase II trial of ixabepilone ...... the children's oncology group
@en
Phase II trial of ixabepilone ...... the children's oncology group
@nl
prefLabel
Phase II trial of ixabepilone ...... the children's oncology group
@ast
Phase II trial of ixabepilone ...... the children's oncology group
@en
Phase II trial of ixabepilone ...... the children's oncology group
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Phase II trial of ixabepilone ...... the children's oncology group
@en
P2093
P2860
P304
P31
P356
10.1158/1078-0432.CCR-09-1906
P407
P433
P478
P50
P577
P698
P921
P932